By giving diazoxide intravenously and furosemide orally the diastolic blood pressure was kept under 110 mm Hg and the urinary output over 1 L/day for a 2-week period in 25 hypertensive patients with azotemia. During the first 2 weeks of treatment three patients died. Although the 40% decrease in mean arterial pressure in the remaining patients was associated with immediate improvement in the cardiovascular status, for example, clearing of congestive heart failure and papilledema, there was a 19% average increase in BUN and 17% average increase in serum creatinine values. Three months later, however, maintenance of the reduced arterial pressure was associated with average reductions of 24 mg/1100 ml in BUN and of 2.8 mg/100 ml in serum creatinine below control values. Each of the patients who remained on therapy continued to do well. Twenty-six months later six additional patients had died. In the remaining 16 patients the average mean arterial pressure was 117 mm Hg; papilledema had cleared; the average concentration of BUN was 22 mg/100 ml; the average serum creatinine was
Papilledema Renal insufficiency
Lowering the arterial pressure with most potent antihypertensive agents including diazoxide in hypertensive azotemic patients has been uniformly unsatisfactory. Although the fall in arterial pressure with diazoxide is associated with an increase in cardiac output and a decrease in total peripheral resistance, treatment with diazoxide also causes a decrease in renal blood flow and a decrease in urinary output and sodium retention.2 The decrease in urinary output and sodium retention can be prevented by the concomitant use of thiazide diuretics in hypertensive patients with normal renal function. Experience in this laboratory has demonstrated, however, that the thiazide diuretics are not sufficiently potent to prevent these diazoxide-induced side effects in patients with impaired renal function.3 Diazoxide administered alone or with thiazide diuretics to hypertensive azotemic patients has consistently aggravated the degree of azotemia and frequently produced conges- Figure 1 Cardiorenal effects of diazocxide and furosemide alone and combined, f = increased, I = decreased, T4 = variable, increased or decreased; MAP = mean arterial pressure; CO = cardiac output. tive heart failure. Increasing the dosage of thiazides has not prevented these side effects.3 The availability of furosemide and the reports of its beneficial effects in high doses, particularly in azotemic patients,4' suggested that combining it with diazoxide might do away with at least some of the detrimental effects of diazoxide in hypertensive azotemic patients. Furosemide by itself has a modest effect on the arterial pressure, a varying effect on the cardiac output and renal blood flow, and produces a marked increase in urinary output and sodium excretion6 ( fig. 1 ). Administering these agents together produces a greater decrease in arterial pressure than that from diazoxide alone, increases cardiac output, and increases urinary sodium excretion and urinary output .7 In 1967, Woods and Blythe8 concluded that the reduction of arterial pressure in patients with malignant hypertension complicated with azotemia did not necessarily result in deterioration of renal function and might result in ' improved survival rates. It was hoped that more aggressive reduction of the arterial pressure while maintaining urinary output and preventing sodium retention might further improve survival rates in such patients. The purpose of the present study, therefore, was to determine the effects of maintaining the diastolic pressure at less than 110 mm Hg and the urinary output greater than 1 L daily for a 2 to 3-week period in a group of severely hypertensive patients with azotemia.
Methods
Twenty-five patients with severe hypertension judged to be essential on clinical grounds were selected -from the clinics and wards of the District of Columbia General Hospital. Their characteristics are outlined in table 1. Each of the patients had been followed regularly in the clinic by the authors for at least 1 year. Each of them was in the accelerated stage of hypertension. Opthalmoscopic examination revealed retinopathy in all Circulation, Volume XL, December 1969 patients; papilledema was present in 20. The heart was enlarged in all 25 patients and congestive heart failure was present in five. The average value for BUN was 62 mg/ 100 ml (range, 35 to 103 mg/ 100 ml) and the average value for serum creatinine was 6.9 mg/ 100 ml (range, 3.5 to 15.2 mg/ 100 ml).
All patients had been receiving reserpine and diurectics plus full doses of methyldopa and either hydralazine or guanethidine or both (table 2). Despite increasing the doses of the antihypertensive agents, the arterial pressure remained uncontrollable, renal function deteriorated, and evidence of progressive cardiac and vascular disease persisted. All the patients were hospitalized except four, who were followed daily for 3 weeks on an out-patient basis during the intensive treatment period. All previous antihypertensive medications were discontinued with the initiation of intensive therapy. The patients were placed on a regular diet with no added salt.
The aim of treatment was to maintain the diastolic pressure continuously below 110 mm Hg and the urinary output over 1 L/day. Since previous experience suggested that a prolonged hypotensive effect following diazoxide was frequently associated with modification of the disease, the end point in these studies was maintenance of the diastolic blood pressure under 110 mm Hg for 24 hours after administration of diazoxide. Diazoxide* was supplied in 20 ml ampules in a concentration of 15 mg/ml and was administered undiluted rapidly intravenously in 300-mg doses as often as needed to maintain the diastolic pressure during recumbency less than 110 mm Hg. Furosemidet was supplied in 2,ml ampules in a concentration of 10 mg/ml for intravenous administration and 40-mg tablets for oral use. Furosemide was administered intravenously or orally in an amount sufficient to maintain a urinary output greater than 1 L/day. The daily dose of furosemide and total number of ampules of diazoxide administered to each patient are tabulated in table 3. After completion of the aggressive treatment period the patients were given maintenance doses of furosemide in an amount sufficient to insure adequate urinary output, for example, more than 1 L/day, and reduced doses of the same antihypertensive medications that they had previously received (table 2) . Serial determinations of blood urea nitrogen,9 serum creatinine,'0 and electrolytes"1 12 were performed by standard technics at appropriate intervals. Creatinine, inulin,13 and para-aminohippuric acid (PAH) clearances'4 were performed on seven patients prior to intensive therapy, at 6 months, and again at 1 year following completion of aggressive therapy.
Patients were considered for peritoneal dialysis at the discretion of the house staff if the complications of uremia could not be controlled by conservative means. Arterial blood pressure was determined by the auscultatory method,'5 and the disappearance of the Korotkoff sound was recorded as the diastolic pressure.'6 The mean arterial pressure was calculated as the sum of the systolic and diastolic pressure divided by two. At the end of the aggressive treatment period patients were followed in the hypertension clinic initially at weekly intervals for 2 months and then at bi-weekly or monthly intervals. The average duration of follow-up in the 22 patients surviving the aggressive treatment period was 26±7 months. Included in the long-term follow-up are the last recorded data on the patients who expired during follow-up (cases 1, 4, 7, 15, 16, and 22).
Results
The effect of intensive therapy on the cardiovascular-renal status is outlined in table 4. The hypotensive effect of diazoxide began 30 seconds after administration and lasted 8 to 12 hours after the first few injections. After repeated doses the duration of hypotension following diazoxide usually increased to 20 to 30 hours. The number of ampules of diazoxide needed to maintain the diastolic pressure under 110 mm Hg varied from 1 ampule in 1 day to 45 ampules in 20 days (table 3) .
Although the arterial pressure was well controlled in all patients, three patients with papilledema (cases 6, 10, and 13), whose control BUN was over 60 mg/ 100 ml, died during the treatment period.
From the cardiovascular standpoint at the time of completion of intensive therapy the remaining 22 patients were markedly improved. The 40% average decrease in mean 3  3  3  3  4  3  3  3  3  3  2  3   3   4   2  3   3  3  3  2  3  2 1.1 1.5 Table 5 Renal Clearances in Seven Patients Prior to Intensive Therapy, 6 The decrease in degree of renal insufficiency in the four patients was most probably explained by improvement in the cardiac hemodynamics, for example by lessening of the congestive heart failure. Despite the high doses of furosemide there were no significant changes in serum sodium or potassium. The only constant side effect of treatment was the production of postural hypotension which lasted 8 to 10 hours and was readily prevented by insisting that the patient remain recumbent for that period after diazoxide administration. At the end of the period of intensive treatment each of the 22 patients had become asymptomatic and was well enough for discharge. Immediately after completion of intensive therapy the dose of furosemide was decreased in all patients and reduced doses of methyldopa or hydralazine were begun (table 2). It was not necessary to institute guanethidine therapy in any patient. This regimen was continued for the remainder of the study with slight adjustment in dosage to maintain the lowered level of arterial pressure and adequate urinary output.
Three months later each of the 22 patients continued to be asymptomatic. The average mean arterial pressure was 118 + 14 mm Hg, the average BUN was 38 18 mg/ 100 ml, and the average serum creatinine was 4.1 2.0 mg/ 100 ml. In this period of time, therefore, there had been an average reduction of 24 mg/ 100 ml in BUN and of 2.8 mg/ 100 ml in serum creatinine from control values.
Six months after intensive treatment the average mean arterial pressure in the 22 patients was 118 + 15 mm Hg, the average BUN was 31 + 18 mg/ 100 ml, and the average serum creatinine was 3.3 + 2.0 mg/ 100 ml. Repeat determinations of inulin and PAH clearances were performed in the seven patients at this time. The results of these clearances can be seen in table 5. Improvement in the inulin and PAH clearances paralleled the decreases in BUN and creatinine.
Twelve months after intensive treatment the average mean arterial pressure was 119 13 mm Hg; the average BUN was 28 15 Serial changes in mean arterial pressure (MAP), blood urea nitrogen (BUN), serum creatinine, inulin clearance (CIN), and para-aminohippurate clearance (CPAH) following intensive antihypertensive treatment in a representative patient (case 15). The status of the cardiovascular-renal dis-5. During the twelfth month patient 16, who ease an average of 26 months after intensive had discontinued medication 1 month earlier, therapy is outlined in table 6 . Five additional died of uremia. His level of BUN when last patients had now died. In the remaining 16 seen in the clinic (a month earlier) was 52 patients the average mean arterial pressure mg/ 100 ml, and his control level of BUN prior was 117 + 11 mm Hg (37% below the to aggressive therapy was 102 mg/ 100 ml. The control). Cardiomegaly was less, congestive serial changes in arterial pressure, serum heart failure had cleared, papilledema had creatinine, BUN, and renal clearance during cleared in all patients, and retinopathy had improved in all but one patient. The average BUN was 22 ± 10 mg/ 100 ml, and the average serum creatinine was 1.8 + 1.1 mg/ 100 ml. It is interesting to analyze the long-term results according to the control levels of BUN (table 6). In the 12 patients in the low BUN group two patients had died. In the remaining 10 patients the BUN and serum creatinine had returned to normal or near normal values (average for BUN, 16+5 mg/ 100 ml; average for creatinine, 1.2 ± 0.5 mg/ 100 ml). In the 13 patients in the high BUN group seven patients had died; three during the period of intensive therapy and four later. In the remaining six patients the average BUN was 32 + 7 mg/ 100 ml, and the average serum creatinine was 2.8 + 1.1 mg/100 ml.
Analysis of Deaths
During the intensive treatment period the three patients who died were in the high BUN group (cases 6, 10, and 13). Two of the patients (cases 6 and 10) died with progressive renal insufficiency despite control of the arterial pressure. Patient 10 underwent peritoneal dialysis. Patient 13 died as a result of a cerebral hemorrhage which probably was present at the time of admission. Lumbar puncture was not performed until the third day after admission because of the presence of papilledema.
After the period of intensive treatment four additional patients in the high BUN 
Discussion
These studies have demonstrated the beneficial effects of acute reduction of arterial pressure and the promotion of diuresis on the cardiovascular system in severely hypertensive patients. Thus, at the end of intensive treatment, congestive heart failure had cleared in four of five patients and the heart size had decreased in eight of 25 patients. At the end of the period of intensive therapy, papilledema had cleared in 16 of 20 patients and retinopathy had decreased in 18 patients. These effects on heart size and congestive heart failure were not surprising. Many investigators17' 18 have shown that rapid reduction of arterial pressure by itself constitutes excellent treatment of congestive heart failure by significantly decreasing the strain on the heart and lessening cardiac work. Whereas these beneficial effects on congestive heart failure are consistently observed in hypertensive patients with good renal function, this is frequently not the case in patients with renal insufficiency. Most antihypertensive agents, particularly when used alone without diuretics, decreased urinary output and produce sodium retention both of which aggravate already impaired renal function and may produce congestive heart failure.19 Experience in this laboratory would indicate that, if the urinary output had not been maintained and sodium retention not prevented in these patients, the reduction of arterial pressure would most probably have been accompanied by worsening of congestive heart failure and azotemia.3
The rapidity of clearing of congestive heart failure, the ease in maintaining normal or near normal levels of arterial pressure, and the general feeling of well-being in most of the patients described was most probably due to the general improvement in the hemodynamic state, particularly the negative sodium balance and lowered arterial pressure. Acute reduction of arterial pressure with diazoxide and furosemide is associated with an increase in cardiac output, decrease in peripheral resistance, and an increase in urinary output and urinary sodium excretion.7 Despite the improved cardiac hemodynamics, renal function was temporarily worsened in all but four patients (cases 2 to 4, and 25). The lack of deterioration of renal function in these four patients is best accounted for by the improved cardiac hemodynamics. That the worsening of renal function in the remainder of the patients was temporary is apparent since 3 months later there was a 37% average reduction in BUN, and a 34% average reduction in serum creatinine below control values. By 6 months the average BUN was 31 ± 18 mg/ 100 ml, and the average serum creatinine was 3.3 ± 2.0 mg/ 100 ml. This reduction in BUN and serum creatinine is further supported by the marked improvement in renal blood flow and glomerular filtration rate in the seven patients studied (table 5) .
It may be argued that gradual reduction (instead of acute reduction) of arterial pressure might prevent even the transitory worsening of renal function. Each of the Circulation, Volume XL, December 1969 patients studied, however, had become resistant to standard antihypertensive therapy which made rapid reduction of arterial pressure necessary to prevent cerebral complications. Experience in this clinic and that of Harrington and Kincaid-Smith20 and others has demonstrated (1) the high incidence of cerebral complications when the arterial pressure is uncontrolled, (2) the longer the arterial pressure is uncontrolled, the greater the danger of cerebral complications, and (3) the grave prognosis once a cerebral complication has occurred. Treatment in these patients has almost universally been of no avail. The lack of benefit of treatment in patient 13, who exhibited signs of a cerebrovascular accident on admission, exemplifies this fact.
Cerebral complications may also be secondary to antihypertensive therapy. Reducing the arterial pressure with agents which decrease cardiac output and particularly those which lower arterial blood pressure by producing postural hypotension may be associated with cerebral complications which greatly worsen the prognosis. The frequency of cerebral ischemia, particularly in arteriosclerotic subjects, associated with reduction of arterial pressure is a common clinical experience. The combination of diazoxide and furosemide lowers arterial pressure, increases cardiac output, and maintains cerebral blood flow in the recumbent position. Avoiding the erect position for 8 to 10 hours after administration of diazoxide insures maintenance of cerebral blood flow and prevents postural hypotension. (Although diazoxide by itself does not produce postural hypotension, the production of negative sodium balance and the decrease in extracellular fluid volume by furosemide in the presence of diazoxide may explain this phenomenon. 21) Prior to the period of aggressive therapy, the arterial pressure had become uncontrollable, and the renal function had deteriorated despite administration of full doses of antihypertensive agents. Following the period of intensive therapy, the arterial pressure could be maintained with reduced doses of these same agents. It should be noted also that whereas guanethidine was needed for 17 patients before, it was not needed after the period of intensive therapy (table 2) . This return of responsiveness to antihypertensive agents once the disease had been modified has been noted previously and seems in no way peculiar to either diazoxide or furosemide but rather to maintenance of arterial blood pressure at normal or near normal levels.' Thus sympathectomy,22 pyrogens,23 the ricefruit diet,24 and a variety of antihypertensive agents have each been followed by improvement in the vascular disease.257 The real importance of the observations reported, in this regard, is not that the hypertensive process could be altered but rather that it could be modified so effectively within a short period of time. Maintenance of arterial pressure less than 110 mm Hg and daily urinary output at more than 1 L/day over a 2 or 3-week period accomplished what Mitchell and associates27 accomplished over a 2-year period with hexamethonium and hydralazine.
The fact that the levels of BUN and serum creatinine were significantly reduced 3 months after intensive therapy and had returned to normal 2 years after intensive treatment in 10 of the 12 patients in the low BUN group suggests that the renal vascular disease in these patients was reversible. Even in patients 4 and 22 who were lost to follow-up, the levels of BUN when last examined in the clinic (23 and 18 months after intensive therapy) were 17 and 25 mg/ 100 ml, respectively (table 6). Such results emphasize the importance of aggressively treating patients before the level of BUN rises above 60 mg/100 ml. The long-term results in the patients in the high BUN group were obviously worse, as seven of 16 patients died. These data also support the plea for aggressively treating patients in the accelerated phase before renal vascular deterioration has proceeded "beyond the point of no return."
Patients in the accelerated phase of hypertension should be treated as medical emergencies, that is, as though hypertensive encephalopathy were present. Although such patients should be thoroughly investigated to rule out curable types of hypertension, it is suggested that treatment be instituted first and investigations be performed after the arterial pressure has been controlled.
Unfortunately there is no accurate clinical method either to estimate the amount of reversible renal function or to predict the prognosis of therapy in patients whose BUN is more than 60 mg/100 ml. It should be reemphasized that in each of the patients presented herein renal function had improved 3 months following intensive therapy and continued to improve in all patients who survived and who were not lost to follow-up.
Even in the patients who were lost to followup renal function had significantly improved when they were last examined in the clinic. The results presented which demonstrate an improvement in renal function in 10 of 13 patients in the high BUN group are in marked contrast to the findings of Harrington and Kincaid-Smith20 who characterized successful treatment as no increase in the level of BUN. These investigators and others2R 29 have also stated that reduction of the arterial pressure in hypertensive uremic patients usually aggravates the degree of renal insufficiency and hastens the downhill course. Until the present study this was also our experience. Mitchell and associates27 have reported that intensive treatment in severely hypertensive azotemic patients improves the mortality, that is provides a 25ao 5-year survival. Woods and Blythe8 reported a 55% 1-year survival in 23 patients. The survival rate reported herein at the end of the first year was 85%. Except for the three patients who died during the period of intensive therapy (cases 6, 10, and 13), no other patient died from either hypertension or renal disease as long as he was followed in the clinic.
It must be emphasized that just prior to the aggressive treatment period the patients studied here had each gone into the accelerated phase of hypertension, the arterial pressure had become higher, and the levels of BUN and serum creatinine had increased above their usual high levels. The fact that therapy was instituted in these patients while they were in an accelerated phase might well have accounted for the excessively high levels of BUN and serum creatinine and, therefore, influenced our results.
The impaired renal function as measured by inulin and PAH clearances in the seven patients studied in the accelerated phase and the significant improvement in these clearances 6 months and 1 year after treatment documents the beneficial effects of treatment and supports the concept that the vascular process can indeed be modified.
The results reported herein are not peculiai to diazoxide or furosemide but seem best explained by the physiologic hemodynamic effects accompanying the reduction in arterial pressure, that is, increase in cardiac output, decrease in total peripheral resistance, increase in urinary output, and prevention of sodium retention. Although parenterally administered hydralazine or nitroprusside may be used in combination with furosemide until diazoxide becomes commercially available, the lack of potency and frequent side effects associated with hydralazine and the difficulty in preparation and administration of nitroprusside limit their usefulness.
It has been hypothesized that malignant hypertension may be a reversible disease and that survival may be possible if life can be maintained for a reasonable period while healing of the arteriolitis is occurring.8 It has also been observed that patients with malignant hypertension and renal insufficiency die during the early stages of treatment before the benefits of remission can be realized.8 The prompt clearing of papilledema and decrease in retinopathy, the significant reduction of BUN and serum creatinine 3 months after treatment, and the improvement in renal blood flow and glomerular filtration rate all adequately attest to the reversibility of the malignant phase of hypertension in most of the patients studied here. It would seem that the physiologic reduction of arterial pressure accomplished by diazoxide and furosemide tided 22 of the 25 patients over until the beneficial effects of a remission could be Circulation, Volume XL, December 1969 realized. From this point on, as long as the patients remained on medication, they continued to improve. It seems, therefore, that if the patients could be kept alive during the period of intensive treatment that their chances for survival for at least 1 to 2 years were greatly increased. These findings are in agreement with those of Woods and Blythe.8 It seems also that aggressive treatment should not be discontinued because of a rise in BUN or serum creatinine for such rises are usually transitory. If further studies verify the reversibility of the malignant phase and the improvement in renal function, it would seem that all patients with severe hypertension, with or without azotemia, would benefit by such aggressive treatment. Such "physiologic reduction" of arterial pressure seems particularly indicated in those patients with only mild impairrnent of renal function, for example, in the low BUN group, since 1% years after intensive treatment the levels of BUN and serum creatinine had returned to near normal in all these patients.
The above studies leave many questions unanswered. The decision to keep the arterial pressure under 110 mm Hg and the urinary output over 1 L/day was arbitrary. Experience in this laboratory and that of others'9 has convinced us that because of their sodiumretaining properties, potent antihypertensive agents should not be used alone in patients with renal insufficiency. It is not known whether keeping the diastolic pressure at a lower level, the urinary output at a higher level, or prolonging the period of intensive therapy would increase the beneficial effect of intensive therapy. Such studies are currently under way in this laboratory.
